Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACXP NASDAQ:GNPX NASDAQ:UPC NASDAQ:XBIO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACXPAcurx Pharmaceuticals$1.47+3.5%$1.93$1.33▼$12.60$6.10M-2.0974,372 shs41,965 shsGNPXGenprex$0.48-7.3%$0.81$0.42▼$55.00$5.69M-0.98396,294 shs195,120 shsUPCUniverse Pharmaceuticals$2.95-3.0%$3.03$2.00▼$11.00$1.71M1.6313,446 shs11,028 shsXBIOXenetic Biosciences$2.90$3.11$1.90▼$13.93$6.64M2.1919,210 shs20,534 shs10 Stocks Set to Soar in 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACXPAcurx Pharmaceuticals-5.96%-7.79%-27.92%-66.74%-88.22%GNPXGenprex-5.29%+19.58%-36.55%-73.14%-95.45%UPCUniverse Pharmaceuticals+6.67%+5.19%+12.80%+37.87%-19.36%XBIOXenetic Biosciences-1.36%-5.23%-4.29%-3.01%+5.84%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACXPAcurx Pharmaceuticals$1.47+3.5%$1.93$1.33▼$12.60$6.10M-2.0974,372 shs41,965 shsGNPXGenprex$0.48-7.3%$0.81$0.42▼$55.00$5.69M-0.98396,294 shs195,120 shsUPCUniverse Pharmaceuticals$2.95-3.0%$3.03$2.00▼$11.00$1.71M1.6313,446 shs11,028 shsXBIOXenetic Biosciences$2.90$3.11$1.90▼$13.93$6.64M2.1919,210 shs20,534 shs10 Stocks Set to Soar in 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACXPAcurx Pharmaceuticals-5.96%-7.79%-27.92%-66.74%-88.22%GNPXGenprex-5.29%+19.58%-36.55%-73.14%-95.45%UPCUniverse Pharmaceuticals+6.67%+5.19%+12.80%+37.87%-19.36%XBIOXenetic Biosciences-1.36%-5.23%-4.29%-3.01%+5.84%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACXPAcurx Pharmaceuticals 2.00Hold$31.002,008.84% UpsideGNPXGenprex 1.00SellN/AN/AUPCUniverse Pharmaceuticals 1.00SellN/AN/AXBIOXenetic Biosciences 1.00SellN/AN/ACurrent Analyst Ratings BreakdownLatest UPC, ACXP, GNPX, and XBIO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/1/2026UPCUniverse Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/21/2026GNPXGenprex Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/20/2026ACXPAcurx Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/20/2026XBIOXenetic Biosciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)(Data available from 6/24/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACXPAcurx PharmaceuticalsN/AN/AN/AN/A$2.07 per shareN/AGNPXGenprexN/AN/AN/AN/A$2.42 per shareN/AUPCUniverse Pharmaceuticals$17.86M0.09N/AN/A$99.64 per share0.03XBIOXenetic Biosciences$2.98M2.23N/AN/A$3.23 per share0.90Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACXPAcurx Pharmaceuticals-$7.97M-$4.05N/AN/AN/AN/A-153.92%-101.69%8/10/2026 (Estimated)GNPXGenprex-$16.23M-$14.14N/AN/AN/AN/A-247.32%-176.73%9/2/2026 (Estimated)UPCUniverse Pharmaceuticals-$3.67MN/AN/AN/AN/AN/AN/AN/AN/AXBIOXenetic Biosciences-$2.68M-$1.20N/AN/AN/A-70.03%-39.28%-33.47%8/7/2026 (Estimated)Latest UPC, ACXP, GNPX, and XBIO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2026Q1 2026GNPXGenprexN/A-$0.64N/A-$0.64N/AN/A5/12/2026Q1 2026ACXPAcurx Pharmaceuticals-$0.59-$0.62-$0.03-$0.62N/AN/A5/12/2026Q1 2026XBIOXenetic BiosciencesN/A-$0.20N/A-$0.20N/A$0.81 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthACXPAcurx PharmaceuticalsN/AN/AN/AN/AN/AGNPXGenprexN/AN/AN/AN/AN/AUPCUniverse PharmaceuticalsN/AN/AN/AN/AN/AXBIOXenetic BiosciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACXPAcurx PharmaceuticalsN/A3.783.78GNPXGenprexN/A5.615.61UPCUniverse PharmaceuticalsN/A4.073.90XBIOXenetic BiosciencesN/A7.937.93Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACXPAcurx Pharmaceuticals11.53%GNPXGenprex14.05%UPCUniverse Pharmaceuticals0.18%XBIOXenetic Biosciences15.12%Insider OwnershipCompanyInsider OwnershipACXPAcurx Pharmaceuticals20.30%GNPXGenprex0.25%UPCUniverse Pharmaceuticals57.38%XBIOXenetic Biosciences7.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACXPAcurx Pharmaceuticals34.30 million3.43 millionNo DataGNPXGenprex2010.93 million10.90 millionNo DataUPCUniverse Pharmaceuticals220560,000240,000N/AXBIOXenetic Biosciences42.29 million2.12 millionNot OptionableUPC, ACXP, GNPX, and XBIO HeadlinesRecent News About These CompaniesXenetic Biosciences, Inc. Announces That Its Collaboration Partner Received Approval From the Israeli Ministry of Health to Conduct Exploratory, Investigator Initiated Study of ...June 4, 2026 | finance.yahoo.comXenetic Biosciences, Inc. Announces That Its Collaboration Partner Received Approval From the Israeli Ministry of Health to Conduct Exploratory, Investigator Initiated Study of DNase I In Combination With Anti-CD19 CAR T Cells in Large B-Cell LymphomaJune 4, 2026 | accessnewswire.comAXenetic Biosciences Showcases Compelling ASCO 2026 Data Demonstrating DNase I Significantly Enhances CAR-T Cell Persistence, Tumor Control, and SurvivalJune 1, 2026 | accessnewswire.comAXenetic Biosciences Reports First Quarter 2026 Financial Results and Highlights Continued Advancement of DNase Oncology PlatformMay 13, 2026 | accessnewswire.comAXenetic Biosciences: Q1 Earnings SnapshotMay 12, 2026 | wtop.comWXenetic Biosciences Grants Equity Award to Interim CEOApril 27, 2026 | theglobeandmail.comXenetic Biosciences, Inc. Announces Abstract Acceptance for Presentation at the 2026 ASCO Annual MeetingApril 22, 2026 | accessnewswire.comAXenetic Biosciences, Inc. Reports Full Year 2025 Financial ResultsMarch 13, 2026 | accessnewswire.comAXenetic Biosciences, Inc. Announces Adjournment of 2025 Annual MeetingDecember 11, 2025 | accessnewswire.comAXenetic extends R&D collaboration with The Scripps Research InstituteNovember 19, 2025 | msn.comXenetic Biosciences, Inc. Extends Research and Development Collaboration with Institute Investigator at Scripps Research to Advance DNase PlatformNovember 19, 2025 | accessnewswire.comAXenetic Biosciences, Inc. Reports Third Quarter 2025 Financial ResultsNovember 13, 2025 | accessnewswire.comAXenetic Biosciences Announces Public Offering PricingOctober 14, 2025 | msn.comXenetic 735,000 share Spot Secondary priced at $6.12October 10, 2025 | msn.comMicron, Galecto And Xenetic Lead This Week's Benzinga Stock Ranking SurgesOctober 10, 2025 | benzinga.comXenetic Biosciences, Inc. Announces Pricing of $4.5 Million Underwritten Offering of Common StockOctober 10, 2025 | accessnewswire.comAXenetic Biosciences, Inc. Reports Second Quarter 2025 Financial ResultsAugust 13, 2025 | accessnewswire.comAXenetic Biosciences Reports Improved Financial PerformanceAugust 13, 2025 | msn.comXenetic Biosciences (XBIO) Reports Q2 Loss, Misses Revenue EstimatesAugust 12, 2025 | zacks.comXenetic Biosciences, Inc. Announces Entry by Collaboration Partner into Clinical Study Agreement to Advance Development of DNase Platform for the Treatment of Large B Cell LymphomaJuly 30, 2025 | accessnewswire.comANew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All Headlines5 Stocks Winning the AI Race While Everyone Watches NVIDIABy Bridget Bennett | May 26, 2026NVIDIA’s Outlook Gains Momentum: Stock Price to FollowBy Thomas Hughes | June 11, 2026Buy CrowdStrike Before the Stock Split? Here's the CaseBy Chris Markoch | June 22, 2026Palo Alto Networks Accelerates Growth 31% on AI DemandBy Thomas Hughes | June 3, 2026The Biggest Opportunity From SpaceX’s IPO May Surprise YouBy Jeffrey Neal Johnson | June 10, 2026UPC, ACXP, GNPX, and XBIO Company DescriptionsAcurx Pharmaceuticals NASDAQ:ACXP$1.47 +0.05 (+3.52%) Closing price 04:00 PM EasternExtended Trading$1.48 +0.01 (+0.34%) As of 07:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections. It also develops ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumonia. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York.Genprex NASDAQ:GNPX$0.48 -0.04 (-7.29%) Closing price 04:00 PM EasternExtended Trading$0.48 -0.01 (-1.24%) As of 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Genprex, Inc., a clinical-stage gene therapy company, focuses on developing gene-based therapies for patients with cancer and diabetes in the United States. The company's lead product candidate is REQORSA (GPX-001), which is in preclinical trials to treat non-small cell lung cancer and small cell lung cancer; and GPX-002, which is in preclinical trials to treat type 1 and type 2 diabetes. Its product pipeline comprises Acclaim-1, which is in phase 2a clinical trial for the treatment of non-small cell lung cancer; Acclaim-2, which is in phase phase 1/2 clinical trial for the treatment of non-small cell lung cancer; and Acclaim-3, which is in phase 1/2 clinical trial for the treatment of small cell lung cancer. The company also develops ONC-001, REQORSA as a monotherapy, which is in phase 1 clinical trial to treat advance non-small cell lung cancer; and ONC-002, REQORSA with Tarceva, which is in phase 2 clinical trial to treat non-small cell lung cancer. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.Universe Pharmaceuticals NASDAQ:UPC$2.95 -0.09 (-2.96%) Closing price 04:00 PM EasternExtended Trading$2.81 -0.14 (-4.71%) As of 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Universe Pharmaceuticals INC, a pharmaceutical company, engages in the manufacture, marketing, distribution, and sale of traditional Chinese medicine derivative products in China. It offers products for the treatment of common chronic health conditions in the elderly for physical wellness and longevity; and cold and flu medications. The company also distributes and sells third-party producers, including biomedical drugs, medical instruments, traditional Chinese medicine pieces products, and dietary supplements. Its customers include pharmaceutical companies, hospitals, clinics, and drugstore chains. The company was incorporated in 2019 and is based in Ji'An, China. Universe Pharmaceuticals INC is a subsidiary of Sununion Holding Group Limited.Xenetic Biosciences NASDAQ:XBIO$2.90 0.00 (0.00%) Closing price 04:00 PM EasternExtended Trading$2.90 0.00 (0.00%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Xenetic Biosciences, Inc. is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. XCART has the potential to fuel a robust pipeline of therapeutic assets targeting high-value oncology indications. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Why KB Home Could Reward Patient Investors Later Tesla's New NHTSA Probe Lands at the Worst Possible Time Meta's Internal Turmoil: Morale Nears 20-Year Low at the Wrong Time ASML’s Chip Dominance Runs Into New Silicon Boundaries Frozen Assets: How Super Micro Puts AI Heat on Ice The SpaceX Sell-Off May Be More Than a Market Overreaction Why These South Korea-Focused ETFs Have More Than Doubled in 2026 Nano Nuclear’s AI Data Center Deal Puts the Stock Back in Focus Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
